• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19.

作者信息

Arabi Yaseen M, Chrousos George P, Meduri G Umberto

机构信息

Intensive Care Department, King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia.

University Research Institute of Maternal and Child Health and Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

Intensive Care Med. 2020 Nov;46(11):2067-2070. doi: 10.1007/s00134-020-06223-y. Epub 2020 Oct 7.

DOI:10.1007/s00134-020-06223-y
PMID:33026460
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7538533/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f599/7538533/8c2d87e111f9/134_2020_6223_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f599/7538533/8c2d87e111f9/134_2020_6223_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f599/7538533/8c2d87e111f9/134_2020_6223_Fig1_HTML.jpg

相似文献

1
The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19.皮质类固醇疗法降低重症 COVID-19 死亡率的十个原因。
Intensive Care Med. 2020 Nov;46(11):2067-2070. doi: 10.1007/s00134-020-06223-y. Epub 2020 Oct 7.
2
Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia.精准皮质类固醇治疗对重症2019新型冠状病毒肺炎的潜在益处。
Signal Transduct Target Ther. 2020 Feb 21;5(1):18. doi: 10.1038/s41392-020-0127-9.
3
The COVID-19 Pandemic and Mayo Clinic Proceedings.新冠疫情与《梅奥诊所学报》
Mayo Clin Proc. 2020 May;95(5):835-836. doi: 10.1016/j.mayocp.2020.04.009. Epub 2020 Apr 18.
4
Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?病毒大流行中的吸入性糖皮质激素：治疗新型冠状病毒肺炎（COVID-19）的方法？
Lancet Respir Med. 2020 Sep;8(9):846-847. doi: 10.1016/S2213-2600(20)30314-3. Epub 2020 Jul 30.
5
Systemic Corticosteroids and Mortality in Severe and Critical COVID-19 Patients in Wuhan, China.系统皮质类固醇治疗对武汉重症和危重症 COVID-19 患者的死亡率的影响。
J Clin Endocrinol Metab. 2020 Dec 1;105(12). doi: 10.1210/clinem/dgaa627.
6
Audio Interview: Dexamethasone and Covid-19.音频访谈：地塞米松与新冠疫情
N Engl J Med. 2020 Jul 23;383(4):e52. doi: 10.1056/NEJMe2025927.
7
[Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].《2019新型冠状病毒肺炎患者使用糖皮质激素的专家共识》
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):183-184. doi: 10.3760/cma.j.issn.1001-0939.2020.03.008.
8
COVID-19: Stay Cool toward Corticosteroids.新冠疫情：对皮质类固醇保持冷静态度。
Keio J Med. 2020 Jun 25;69(2):27-29. doi: 10.2302/kjm.2020-0007-LE. Epub 2020 May 30.
9
A Surge in Methanol Poisoning Amid COVID-19 Pandemic: Why Is This Occurring?新冠疫情期间甲醇中毒事件激增：为何会出现这种情况？
Am J Med Sci. 2020 Aug;360(2):201. doi: 10.1016/j.amjms.2020.05.019. Epub 2020 May 20.
10
Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis.糖皮质激素治疗 2019 冠状病毒病相关急性呼吸窘迫综合征：一项倾向评分分析的队列研究。
Crit Care. 2020 Nov 10;24(1):643. doi: 10.1186/s13054-020-03340-4.

引用本文的文献

1
How inflammation influences psychiatric disease.炎症如何影响精神疾病。
World J Psychiatry. 2024 Mar 19;14(3):342-349. doi: 10.5498/wjp.v14.i3.342.
2
Efficacy and Safety Comparison of Two Different Doses of Dexamethasone in Hospitalized Patients with COVID-19: A Randomized Clinical Trial.两种不同剂量地塞米松对 COVID-19 住院患者的疗效与安全性比较：一项随机临床试验
J Res Pharm Pract. 2023 Aug 29;11(4):136-143. doi: 10.4103/jrpp.jrpp_42_22. eCollection 2022 Oct-Dec.
3
Corticosteroid outcome may be dependent of duration of use in severe COVID-19.

本文引用的文献

1
Re-analysis of Single Cell Transcriptome Reveals That the NR3C1-CXCL8-Neutrophil Axis Determines the Severity of COVID-19.单细胞转录组再分析显示 NR3C1-CXCL8-中性粒细胞轴决定了 COVID-19 的严重程度。
Front Immunol. 2020 Aug 28;11:2145. doi: 10.3389/fimmu.2020.02145. eCollection 2020.
2
A living WHO guideline on drugs for covid-19.关于新冠病毒药物的世界卫生组织实用指南。
BMJ. 2020 Sep 4;370:m3379. doi: 10.1136/bmj.m3379.
3
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
皮质类固醇的疗效可能取决于在重症 COVID-19 中的使用时间。
Korean J Intern Med. 2023 May;38(3):382-392. doi: 10.3904/kjim.2022.201. Epub 2023 Apr 11.
4
An Integrated Radiologic-Pathologic Understanding of COVID-19 Pneumonia.新型冠状病毒肺炎的放射-病理综合理解
Radiology. 2023 Feb;306(2):e222600. doi: 10.1148/radiol.222600. Epub 2023 Jan 17.
5
Early dexamethasone use as a protective measure in non-mechanically ventilated critically ill patients with COVID-19: a multicenter, cohort study.COVID-19 非机械通气危重症患者中早期使用地塞米松作为保护措施的多中心队列研究。
Sci Rep. 2022 Jun 13;12(1):9766. doi: 10.1038/s41598-022-13239-5.
6
Usage of compromised lung volume in monitoring steroid therapy on severe COVID-19.使用受损肺容积监测重症 COVID-19 的类固醇治疗。
Respir Res. 2022 Apr 29;23(1):105. doi: 10.1186/s12931-022-02025-6.
7
Remdesivir plus Dexamethasone in COVID-19: A cohort study of severe patients requiring high flow oxygen therapy or non-invasive ventilation.瑞德西韦联合地塞米松治疗 COVID-19：需要高流量氧疗或无创通气的重症患者的队列研究。
PLoS One. 2022 Apr 28;17(4):e0267038. doi: 10.1371/journal.pone.0267038. eCollection 2022.
8
[Noninvasive respiratory support and invasive ventilation in COVID‑19 : Where do we stand today?].[新型冠状病毒肺炎中的无创呼吸支持与有创通气：我们目前的状况如何？]
Anaesthesist. 2022 May;71(5):333-339. doi: 10.1007/s00101-022-01114-x. Epub 2022 Apr 9.
9
Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19.等待新冠病毒病的治愈方法：针对不同严重程度新冠病毒病患者的治疗方法
Infez Med. 2022 Mar 1;30(1):11-21. doi: 10.53854/liim-3001-2. eCollection 2022.
10
Special Issue "Pulmonary and Critical Care Practice in the Pandemic of COVID-19".特刊“COVID-19大流行中的肺部与重症监护实践”
J Clin Med. 2022 Feb 28;11(5):1336. doi: 10.3390/jcm11051336.
羟考酮治疗对严重 COVID-19 患者死亡率和器官支持的影响：REMAP-CAP COVID-19 皮质类固醇随机临床试验。
JAMA. 2020 Oct 6;324(13):1317-1329. doi: 10.1001/jama.2020.17022.
4
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.地塞米松对中重度 COVID-19 相关急性呼吸窘迫综合征患者存活天数和无呼吸机天数的影响：CoDEX 随机临床试验。
JAMA. 2020 Oct 6;324(13):1307-1316. doi: 10.1001/jama.2020.17021.
5
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.COVID-19 重症患者全身使用皮质类固醇与死亡率的关联：一项荟萃分析。
JAMA. 2020 Oct 6;324(13):1330-1341. doi: 10.1001/jama.2020.17023.
6
Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.COVID-19 重症患者中氢化可的松对 21 天死亡率或呼吸支持的影响：一项随机临床试验。
JAMA. 2020 Oct 6;324(13):1298-1306. doi: 10.1001/jama.2020.16761.
7
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
8
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study.意大利北部一系列 COVID-19 病例的肺脏尸检结果：一项两中心描述性研究。
Lancet Infect Dis. 2020 Oct;20(10):1135-1140. doi: 10.1016/S1473-3099(20)30434-5. Epub 2020 Jun 8.
9
Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung.糖皮质激素抑制人肺中I型干扰素β信号传导及CD73的上调。
Intensive Care Med. 2020 Oct;46(10):1937-1940. doi: 10.1007/s00134-020-06086-3. Epub 2020 May 19.
10
Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019.2019冠状病毒病所致急性呼吸窘迫综合征长期使用皮质类固醇治疗的理论依据
Crit Care Explor. 2020 Apr 29;2(4):e0111. doi: 10.1097/CCE.0000000000000111. eCollection 2020 Apr.